A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

The drug being tested in this study is called zasocitinib. Zasocitinib is being tested to assess the effect of zasocitinib on the pharmacokinetics of Combined Oral Contraceptive (COC \[containing LNG and EE\] in Part 1), multidrug and toxic compound extrusion (MATE) substrate (metformin in Part 2), and a P-glycoprotein (P-gp) substrate (digoxin in Part 3). Additionally, the effect of proton-pump inhibitor (PPI) (esomeprazole in Part 4) on the pharmacokinetics of zasocitinib is being evaluated in healthy participants. The study will enroll approximately 78 participants. Participants will be enrolled in one of the four parts to evaluate the following treatments: * Part 1: COC (LNG and EE) + Zasocitinib * Part 2: Metformin + Zasocitinib * Part 3: Digoxin + Zasocitinib * Part 4: Zasocitinib + Esomeprazole The overall time (including screening and follow-up periods) to participate is approximately 68 days for Part 1, 54 days for Part 2, 62 days for Part 3 and 56 days for Part 4. All participants will be followed up for up to 14 days after the last dose of Period 2 in each Part.